Ozanimod hydrochloride - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for ozanimod hydrochloride and what is the scope of freedom to operate?
Ozanimod hydrochloride
is the generic ingredient in one branded drug marketed by Celgene Intl and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ozanimod hydrochloride has one hundred and fifty-two patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for ozanimod hydrochloride
| International Patents: | 152 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 10 |
| Clinical Trials: | 28 |
| Patent Applications: | 18 |
| What excipients (inactive ingredients) are in ozanimod hydrochloride? | ozanimod hydrochloride excipients list |
| DailyMed Link: | ozanimod hydrochloride at DailyMed |
Recent Clinical Trials for ozanimod hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bristol-Myers Squibb | Phase 3 |
| Bristol-Myers Squibb | Phase 4 |
| Bristol-Myers Squibb | Phase 2/Phase 3 |
US Patents and Regulatory Information for ozanimod hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-002 | Mar 25, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ozanimod hydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Malaysia | 156381 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | See Plans and Pricing |
| China | 102762100 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | See Plans and Pricing |
| Lithuania | 2498610 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ozanimod hydrochloride
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2498610 | CA 2020 00053 | Denmark | See Plans and Pricing | PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORIDE; REG. NO/DATE: EU/1/20/1442 20200525 |
| 2498610 | PA2020533,C2498610 | Lithuania | See Plans and Pricing | PRODUCT NAME: OZANIMODAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC OZANIMODO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/20/1442 20200520 |
| 2291080 | CA 2020 00047 | Denmark | See Plans and Pricing | PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORID; REG. NO/DATE: EU/1/20/1442 20200520 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
